all report title image

GLOBAL CELL PENETRATING PEPTIDE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Cell Penetrating Peptide Market, By Type (Protein Derived CPPs, Synthetic CPPs, Chimeric CPPs), By Application (Drug Delivery, Gene Delivery, Diagnostics, Molecular Imaging, Others), By End User (Biopharmaceutical Companies, Contract Research Organization (CROs)/CDMO, Hospitals and Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published In : Jan 2024
  • Code : CMI6553
  • Pages :179
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Cell penetrating peptides (CPPs) are short sequences of amino acids that are able to cross cell membranes and deliver attached bioactive cargo such as antibodies, nucleic acids, and chemotherapeutics into cells. Their ability to traverse barriers has made them important molecular transporters, enabling the delivery of various investigational and approved therapeutics. The market has witnessed considerable research on optimizing Cell penetrating peptides (CPPs) sequences and conjugation techniques to improve pharmacological properties such as stability, solubility, and cellular uptake efficiency. With growing interest in developing CPP-based delivery strategies for diseases like cancer, neurodegeneration, and chronic infections, the cell penetrating peptide market is anticipated to grow at a rapid pace in the future.

CPPs offer numerous advantages over traditional transfection methods as they provide a non-invasive, efficient, and rapid delivery of cargo molecules into live cells under physiological conditions. Given their easy molecular conjugation and biocompatible uptake, CPPs hold immense potential for research and therapeutic applications including protein therapy, gene delivery, and diagnostic imaging. However, their non-selective bilayer disruption and possible cytotoxicity at higher concentrations remain major challenges. Improved design strategies aim to develop safer and more target-specific CPPs.

 Market Dynamics:

The cell penetrating peptide market is driven by rising incidences of diseases such as cancer and others requiring intracellular delivery of therapeutics, increasing research and development, investments by pharmaceutical companies, and growing adoption of peptide-based drugs. However, challenges pertaining to poor stability, unpredictable toxicity, and immune response inhibition associated with some CPPs hamper market growth. Ongoing research to engineer newer generations of non-toxic and biocompatible peptide sequences presents significant opportunities.

Thus, the increasing prevalence of cancer is expected to propel market growth over the forecast period. For instance, according to the data published by the American Cancer Society in 2021, cancer facts and figures in the U.S. reported the estimated number of cancer cases in the U.S. in 2021, which is provided below:

ESTIMATED NEW CANCER CASES IN THE U.S. IN 2021

 Female Breast Cancer

 Lung & bronchus

Melanoma of the skin

Urinary bladder

 Prostate

Colon & rectum

Uterine

cervix

Uterine

corpus

     Leukemia

Non Hodgkin

lymphoma

281,550

235,760

106,110

83,730

248,530

149,500

281,550

149,500

61,090

81,560

Key features of the study:

  • This report provides in-depth analysis of the global cell penetrating peptide market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cell penetrating peptide market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AnaSpec, Peptomyc, BioAlps, Sarepta Therapeutics, Inc., REVANCE THERAPEUTICS, PolyPeptide Group, Bachem, Pepscan Creative Peptides, Cupidpeptides and AltaBioscience Ltd
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global cell penetrating peptide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell penetrating peptide market

Detailed Segmentation:

  • Global Cell Penetrating Peptide Market, By Type
    • Protein Derived CPPs
    • Synthetic CPPs
    • Chimeric CPPs
  • Global Cell Penetrating Peptide Market, By Application
    • Drug Delivery
    • Gene Delivery
    • Diagnostics
    • Molecular Imaging
    • Others
  • Global Cell Penetrating Peptide Market, By End User
    • Biopharmaceutical Companies
    • Contract Research Organization (CROs)/CDMO
    • Hospitals and Clinics
    • Others
  • Global Cell Penetrating Peptide Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Global Cell Penetrating Peptide Market, Key Players
    • AnaSpec
    • Peptomyc
    • BioAlps
    • Sarepta Therapeutics, Inc.
    • REVANCE THERAPEUTICS
    • PolyPeptide Group
    • Bachem
    • Pepscan
    • Creative Peptides
    • Cupidpeptides
    • AltaBioscience Ltd

Global Cell Penetrating Peptide Market- Segmentation

  • By Type
    • Protein Derived CPPs
    • Synthetic CPPs
    • Chimeric CPPs
  • By Application
    • Drug Delivery
    • Gene Delivery
    • Diagnostics
    • Molecular Imaging
    • Others
  • By End User
    • Biopharmaceutical Companies
    • Contract Research Organization (CROs)/CDMO
    • Hospitals and Clinics
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.